Expert Opinion

Future of maintenance therapy in multiple myeloma

Where is maintenance therapy heading?

Professor Meletios Dimopoulos, Professor Philippe Moreau and Dr Niels Van de Donk discuss the evidence currently available regarding the influence of maintenance therapy on patient outcomes in multiple myeloma and potential future treatment options.

The views expressed in this video are those of the speakers.

UK/NP/1806/0035am - August 2018

Get updates from the Myeloma Hub

Be the first to know about new content and features on the Myeloma Hub.

Sign up
Also on the Hub…
Knowledge Centre Expert Opinion Congresses Guidelines
About
Faculty Contact us Terms of Use Privacy policy

Myeloma Hub is for UK healthcare professionals treating patients with multiple myeloma. This website has been provided by Takeda Oncology.

Takeda Oncology and Takeda are registered trademarks of Takeda Pharmaceutical Company Limited. Other trademarks are the property of their respective owners. © Takeda UK Limited, 2018. Registered office: Takeda UK Limited, Building 3, Glory Park, Glory Park Avenue, Wooburn Green, Bucks, HP10 0DF. Registered in England and Wales No. 3362860. UK/NP/1806/0035x-July 2018

You are now leaving the Myeloma Hub

This link opens another website that is not under the review or control of Takeda UK Ltd and, as such, the company does not endorse the content, its accuracy, or any practices or standards contained within it. Please confirm you wish to continue.

Cancel Continue to link

UK/NP/1806/0035az - August 2018